{"id":432699,"date":"2021-02-10T07:18:11","date_gmt":"2021-02-10T12:18:11","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=432699"},"modified":"2021-02-10T07:18:11","modified_gmt":"2021-02-10T12:18:11","slug":"actinium-announces-participation-in-bio-ceo-investor-digital-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/","title":{"rendered":"Actinium Announces Participation in BIO CEO & Investor Digital Conference"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, Feb. 10, 2021<\/span> \/PRNewswire\/ — Actinium Pharmaceuticals, Inc.<\/b>\u00a0 (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that management will participate in the BIO CEO & Investor conference, which is being held digitally February 16<\/span> \u2013 18, 2021. <\/p>\n

\n

\n
\n \"(PRNewsfoto\/Actinium
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Members of Actinium’s executive team will be available for one-on-one meetings with conference attendees. \u00a0Those interested in scheduling a meeting may do so through the BIO One-on-One Partnering\u2122 system https:\/\/www.bio.org\/events\/bio-ceo-investor-digital-conference\/partnering<\/a> or by contacting the Company at investorrelations@actiniumpharma.com<\/a>. <\/p>\n

\n About Actinium Pharmaceuticals, Inc. (NYSE: ATNM)<\/b>\n <\/p>\n

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radioisotopes.\u00a0 Actinium’s lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a Bone Marrow Transplant (BMT), Gene Therapy or Adoptive Cell Therapy such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities.\u00a0 With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently.\u00a0 Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning.\u00a0 The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings.\u00a0 More information on this Phase 3 clinical trial can be found at www.sierratrial.com<\/a>. I-131 apamistamab is also be studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell therapy in collaboration with Memorial Sloan Kettering Cancer Center for which we have been awarded NIH grant funding.\u00a0 In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.\u00a0 Ongoing combination trials include our CD33 ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax.\u00a0 Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform.\u00a0 This is where our intellectual property portfolio of over 130 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes.\u00a0 Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc. Website: www.actiniumpharma.com<\/a><\/p>\n

\n Forward-Looking Statements for Actinium Pharmaceuticals, Inc.\u00a0<\/b>\n <\/p>\n

This press release may contain projections or other “forward-looking statements” within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.<\/p>\n

\n Contacts:<\/b>\n <\/p>\n

Investors:<\/p>\n

Hans Vitzthum\u00a0
LifeSci Advisors, LLC
Hans@LifeSciAdvisors.com<\/a>
<\/u>(617) 430-7578<\/p>\n

Actinium Pharmaceuticals, Inc.
investorrelations@actiniumpharma.com<\/a><\/p>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/actinium-announces-participation-in-bio-ceo–investor-digital-conference-301225702.html<\/a><\/p>\n

SOURCE Actinium Pharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, Feb. 10, 2021 \/PRNewswire\/ — Actinium Pharmaceuticals, Inc.\u00a0 (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that management will participate in the BIO CEO & Investor conference, which is being held digitally February 16 \u2013 18, 2021. Members of Actinium’s executive team will be available for one-on-one meetings with conference attendees. \u00a0Those interested in scheduling a meeting may do so through the BIO One-on-One Partnering\u2122 system https:\/\/www.bio.org\/events\/bio-ceo-investor-digital-conference\/partnering or by contacting the Company at investorrelations@actiniumpharma.com. About Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radioisotopes.\u00a0 Actinium’s lead application for our ARCs is targeted … <\/p>\n

Continue reading “Actinium Announces Participation in BIO CEO & Investor Digital Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-432699","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nActinium Announces Participation in BIO CEO & Investor Digital Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Actinium Announces Participation in BIO CEO & Investor Digital Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Feb. 10, 2021 \/PRNewswire\/ — Actinium Pharmaceuticals, Inc.\u00a0 (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that management will participate in the BIO CEO & Investor conference, which is being held digitally February 16 \u2013 18, 2021. Members of Actinium’s executive team will be available for one-on-one meetings with conference attendees. \u00a0Those interested in scheduling a meeting may do so through the BIO One-on-One Partnering\u2122 system https:\/\/www.bio.org\/events\/bio-ceo-investor-digital-conference\/partnering or by contacting the Company at investorrelations@actiniumpharma.com. About Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radioisotopes.\u00a0 Actinium’s lead application for our ARCs is targeted … Continue reading "Actinium Announces Participation in BIO CEO & Investor Digital Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-10T12:18:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/730678\/Actinium_Pharmaceuticals_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Actinium Announces Participation in BIO CEO & Investor Digital Conference\",\"datePublished\":\"2021-02-10T12:18:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\\\/\"},\"wordCount\":680,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/730678\\\/Actinium_Pharmaceuticals_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\\\/\",\"name\":\"Actinium Announces Participation in BIO CEO & Investor Digital Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/730678\\\/Actinium_Pharmaceuticals_Logo.jpg\",\"datePublished\":\"2021-02-10T12:18:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/730678\\\/Actinium_Pharmaceuticals_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/730678\\\/Actinium_Pharmaceuticals_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actinium Announces Participation in BIO CEO & Investor Digital Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Actinium Announces Participation in BIO CEO & Investor Digital Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/","og_locale":"en_US","og_type":"article","og_title":"Actinium Announces Participation in BIO CEO & Investor Digital Conference - Market Newsdesk","og_description":"PR Newswire NEW YORK, Feb. 10, 2021 \/PRNewswire\/ — Actinium Pharmaceuticals, Inc.\u00a0 (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that management will participate in the BIO CEO & Investor conference, which is being held digitally February 16 \u2013 18, 2021. Members of Actinium’s executive team will be available for one-on-one meetings with conference attendees. \u00a0Those interested in scheduling a meeting may do so through the BIO One-on-One Partnering\u2122 system https:\/\/www.bio.org\/events\/bio-ceo-investor-digital-conference\/partnering or by contacting the Company at investorrelations@actiniumpharma.com. About Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radioisotopes.\u00a0 Actinium’s lead application for our ARCs is targeted … Continue reading \"Actinium Announces Participation in BIO CEO & Investor Digital Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-10T12:18:11+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/730678\/Actinium_Pharmaceuticals_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Actinium Announces Participation in BIO CEO & Investor Digital Conference","datePublished":"2021-02-10T12:18:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/"},"wordCount":680,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/730678\/Actinium_Pharmaceuticals_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/","name":"Actinium Announces Participation in BIO CEO & Investor Digital Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/730678\/Actinium_Pharmaceuticals_Logo.jpg","datePublished":"2021-02-10T12:18:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/730678\/Actinium_Pharmaceuticals_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/730678\/Actinium_Pharmaceuticals_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-announces-participation-in-bio-ceo-investor-digital-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Actinium Announces Participation in BIO CEO & Investor Digital Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/432699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=432699"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/432699\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=432699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=432699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=432699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}